TargeLead
TM
应用于药物筛选
应用案例
GSK | GSK 2982772 | RIP1 inhibitor | Phase-II clinical trials
GSK advanced its compound GSK2982772—which came about from DNA-encoded library work—to Phase IIa clinical trials in patients with psoriasis, rheumatoid arthritis, and ulcerative colitis. GSK2982772 inhibits receptor interacting protein 1 kinase, or RIP1 kinase, an enzyme that’s been linked to inflammation.
Looking to develop an inhibitor for RIP1 kinase, scientists at GSK first screened the company’s set of known kinase inhibitors, but they were unable to find molecules that had the druglike properties they were looking for, and they also found that hits from this set of compounds weren’t selective for RIP1; they inhibited other kinases as well.
They also screened GSK’s high-throughput collection of roughly 2 million compounds and identified a RIP1 inhibitor, but that compound had challenges. In particular, it didn’t get into the bloodstream of rodents when given orally. By far the most promising lead, a compound known as GSK´481, was obtained by screening a DNA-encoded library of approximately 7.7 billion compounds against RIP1 kinase. GSK´481 turned out to be extremely potent as well as highly specific to RIP1 kinase (J. Med. Chem. 2016, DOI: 10.1021/acs.jmedchem.5b01898).
But the scientists thought they could improve GSK´481’s pharmacokinetics. Using a traditional medicinal chemistry approach, they eventually wound up swapping GSK´481’s isoxazole for a triazole to get their clinical candidate GSK2982772 (J. Med. Chem. 2017, DOI: 10.1021/acs.jmedchem.6b01751).
快速搭建DELs新药筛选平台
BIOASSIST为新药研发企业搭建标准的DELs化合物筛选平台提供
全面技术支持
新一代筛选技术 DELs技术在新药研发领域的应用日益广泛,其低成本、短周期、高效率的技术优势让DELs逐渐成为发现创新型小分子化合物的重要技术手段
快速实现 BIOASSIST为新药研发的企业提供基于DELs技术的完整解决方案,从实验室硬件搭建到技术人员操作培训,快速协助企业建立标准的DELs筛选平台
助力新药研发 BIOASSIST为企业建立新靶点的筛选验证条件提供支持,助力自主创新药物开发